Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older

Completed · Phase 3

Conditions studied: Cystic Fibrosis

In brief

The study evaluates the long-term safety, tolerability, efficacy, and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in participants with cystic fibrosis (CF).

Key facts

Study ID
NCT04183790
Run by
Vertex Pharmaceuticals Incorporated
People needed
64
Starts
2020-02-17
Expected to finish
2024-02-24
Last updated by the study team
2025-05-18

Who can join

Age: 6 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.